Skip to Main Content

Sage Therapeutics said Tuesday that an experimental pill designed to alleviate depression with a two-week course of therapy was successful in a large clinical trial involving patients with major depressive disorder.

The Sage drug, called zuranolone, demonstrated a statistically significant, anti-depressive benefit compared to a placebo. The positive results are a comeback win for Sage and its efforts to develop zuranolone for several different depressive disorders. The drug failed a similar study in December 2019.


However, the benefit of zuranolone in the study appears to be relatively small, raising questions about the drug’s commercial potential. Sage’s stock price dropped in Tuesday’s pre-market trading, after the results were announced.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.